


NCCN Trends™ is an analytics tool from the National Comprehensive Cancer Network® (NCCN®) that surveys how clinicians across the U.S. and around the globe are delivering cancer care. This summary includes the results of the April 2013 NCCN Trends™ Survey, which focused on Multiple Meloma. This survey was sent to U.S. and International users of NCCN.org.


DEMOGRAPHICS †

Distribution of Respondent Types (n = 1,225)




†Note: Percentages may not total 100 because of rounding.

Q1. Do you treat patients with multiple myeloma (MM)? (n = 892)



Q2. Over the past 12 months, how many total number of unique patients with MM have you personally managed? (n = 404)


Please note that this question is asking for the total number of patients with MM (not patient visits) managed by you, personally, not those managed by your entire practice/network. Also, please include patients who are referred to you to establish treatment and then returned to the referring physician for ongoing management (if applicable).



Q2. Over the past 12 months, how many total number of unique patients with MM have you personally managed?

Please note that this question is asking for the total number of patients with MM (not patient visits) managed by you, personally, not those managed by your entire practice/network. Also, please include patients who are referred to you to establish treatment and then returned to the referring physician for ongoing management (if applicable).

By Geography †




†Note: Percentages may not total 100 because of rounding.

Q2. Over the past 12 months, how many total number of unique patients with MM have you personally managed?

Please note that this question is asking for the total number of patients with MM (not patient visits) managed by you, personally, not those managed by your entire practice/network. Also, please include patients who are referred to you to establish treatment and then returned to the referring physician for ongoing management (if applicable).

By Practice Size †




†Note: Percentages may not total 100 because of rounding.

Q2. Over the past 12 months, how many total number of unique patients with MM have you personally managed?

Please note that this question is asking for the total number of patients with MM (not patient visits) managed by you, personally, not those managed by your entire practice/network. Also, please include patients who are referred to you to establish treatment and then returned to the referring physician for ongoing management (if applicable).

By Practice Setting †




†Note: Percentages may not total 100 because of rounding.

Q2. Over the past 12 months, how many total number of unique patients with MM have you personally managed?


Please note that this question is asking for the total number of patients with MM (not patient visits) managed by you, personally, not those managed by your entire practice/network. Also, please include patients who are referred to you to establish treatment and then returned to the referring physician for ongoing management (if applicable).

By Specialty †



†Note: Percentages may not total 100 because of rounding.



Q3. Consider the recent addition of carfilzomib/lenalidomide/dexamethasone (RCd) to the NCCN Guidelines for Multiple Myeloma under 'Other Regimen' for primary therapy for transplant candidates, how do you expect your prescribing of the following carfilzomib-based regimens to change over the next 6 months? (n = 333) †



†Note: Percentages may not total 100 because of rounding.

Q3. Consider the recent addition of carfilzomib/lenalidomide/dexamethasone (RCd) to the NCCN Guidelines for Multiple Myeloma under 'Other Regimen' for primary therapy for transplant candidates, how do you expect your prescribing of the following carfilzomib-based regimens to change over the next 6 months?

By Geography †*





*Continued on Page 10

†Note: Percentages may not total 100 because of rounding.

Q3. Consider the recent addition of carfilzomib/lenalidomide/dexamethasone (RCd) to the NCCN Guidelines for Multiple Myeloma under 'Other Regimen' for primary therapy for transplant candidates, how do you expect your prescribing of the following carfilzomib-based regimens to change over the next 6 months?

By Geography †*


*Continued from Page 9



†Note: Percentages may not total 100 because of rounding.

Q3. Consider the recent addition of carfilzomib/lenalidomide/dexamethasone (RCd) to the NCCN Guidelines for Multiple Myeloma under 'Other Regimen' for primary therapy for transplant candidates, how do you expect your prescribing of the following carfilzomib-based regimens to change over the next 6 months?

By Practice Size †*





*Continued on Page 12

†Note: Percentages may not total 100 because of rounding.

Q3. Consider the recent addition of carfilzomib/lenalidomide/dexamethasone (RCd) to the NCCN Guidelines for Multiple Myeloma under 'Other Regimen' for primary therapy for transplant candidates, how do you expect your prescribing of the following carfilzomib-based regimens to change over the next 6 months?

By Practice Size †*


*Continued from Page 11



†Note: Percentages may not total 100 because of rounding.

Q3. Consider the recent addition of carfilzomib/lenalidomide/dexamethasone (RCd) to the NCCN Guidelines for Multiple Myeloma under 'Other Regimen' for primary therapy for transplant candidates, how do you expect your prescribing of the following carfilzomib-based regimens to change over the next 6 months?

By Practice Setting †*





*Continued on Page 14

†Note: Percentages may not total 100 because of rounding.

Q3. Consider the recent addition of carfilzomib/lenalidomide/dexamethasone (RCd) to the NCCN Guidelines for Multiple Myeloma under 'Other Regimen' for primary therapy for transplant candidates, how do you expect your prescribing of the following carfilzomib-based regimens to change over the next 6 months?

By Practice Setting †*


*Continued from Page 13



†Note: Percentages may not total 100 because of rounding.

Q3. Consider the recent addition of carfilzomib/lenalidomide/dexamethasone (RCd) to the NCCN Guidelines for Multiple Myeloma under 'Other Regimen' for primary therapy for transplant candidates, how do you expect your prescribing of the following carfilzomib-based regimens to change over the next 6 months?

By Specialty †*




*Continued on Page 16

†Note: Percentages may not total 100 because of rounding.

Q3. Consider the recent addition of carfilzomib/lenalidomide/dexamethasone (RCd) to the NCCN Guidelines for Multiple Myeloma under 'Other Regimen' for primary therapy for transplant candidates, how do you expect your prescribing of the following carfilzomib-based regimens to change over the next 6 months?

By Specialty †*

*Continued from Page 15



†Note: Percentages may not total 100 because of rounding.

NCCN Trends™ is an analytics tool from the National Comprehensive Cancer Network® (NCCN®) that surveys how clinicians across the U.S. and around the globe are delivering cancer care. NCCN Trends™ surveys are designed to reach targeted populations that can include several thousand clinicians as a potential sample size. NCCN can also provide analytics on existing NCCN Trends™ and clinician demographic data sets, allowing for greater insight into oncology practice patterns.

To commission an **NCCN Trends™** survey, to discuss analytic and data services, or to request information on other NCCN programs and resources, please contact:

Christine MacCracken, MSHEd, BSN
Senior Director, Business Insights
215.690.0557
maccracken@nccn.org

National Comprehensive Cancer Network® (NCCN®)

The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 21 of the world's leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers. The primary goal of all NCCN initiatives is to improve the quality, effectiveness, and efficiency of oncology practice so patients can live better lives.



National
Comprehensive
Cancer
Network®

275 Commerce Drive • Suite 300
Fort Washington, PA, 19034
Telephone: 215.690.0300
Fax: 215.690.0280

NCCN.org - For Clinicians • NCCN.com - For Patients

*All NCCN Trends™ survey content and resulting data are owned by NCCN. Survey responses are made anonymous to protect the privacy of survey respondents. NCCN may license survey content, data, and analytic results to third parties, but retains the rights to use this data for other purposes, including the support of educational and research efforts or for other strategic or business purposes.